A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS)

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

开始日期2023-04-06

申办/合作机构

上海医药集团股份有限公司

CTR20230026

/ Recruiting临床2期

一项在急性缺血性脑卒中（AIS）受试者中评价注射用 LT3001 的安全性和有效性的多中心、随机、双盲、安慰剂平行对照的 II 期临床研究

主要目的：评价多次给予注射用 LT3001 治疗急性缺血性脑卒中（AIS）患者的安全性。次要目的：评价多次给予注射用 LT3001 治疗急性缺血性脑卒中（AIS）患者的有效性。

开始日期2023-04-06

申办/合作机构

顺天医药生技股份有限公司

[+2]

NCT05403866

/ Completed临床2期

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS)

This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)

开始日期2022-08-17

申办/合作机构

顺天医药生技股份有限公司

100 项与 Odatroltide 相关的临床结果

登录后查看更多信息

100 项与 Odatroltide 相关的转化医学

登录后查看更多信息

100 项与 Odatroltide 相关的专利（医药）

登录后查看更多信息

项与 Odatroltide 相关的文献（医药）

2026-01-01·BIOORGANIC & MEDICINAL CHEMISTRY

Synthesis of 7-azaindoles and their pro-angiogenic and anti-inflammatory activities

Article

作者: Yang, Weiwei ; Luo, Zhongfeng ; Zeng, Wei ; Zou, Lifang ; Lu, Zibing ; Tan, Zhenyou ; Liu, Junshan

Azaindole skeletons are prevalent in both natural products and pharmaceuticals, and they exhibit excellent biological activity. However, efficient synthetic strategies for accessing these compounds remain limited. Here, we synthesized a series of 7-azaindoles I-1-I-52 including 10 new compounds I-34 - I-43via double Csp²-H bond activations. The structures of these compounds were characterized using ¹H NMR, ¹³C NMR, and HR-MS. Their biological activities were evaluated in zebrafish models. The in vivo bioactivity data showed compounds I-47 and I-51 have significant pro-angiogenic effects, while compounds I-17, I-29, I-35 and I-37 exert potent anti-inflammatory effects. Moreover, the new compound I-37 alleviated inflammation in a concentration-dependent manner in both mechanical injury and lipopolysaccharide-induced inflammation models, which was associated with the inhibition of TNF-α and IL-6. This study not only provides a novel strategy for the synthesis of 7-azaindoles but also supports candidate compounds with pro-angiogenic and anti-inflammatory effects.

2024-02-01·Translational stroke research

Effects of the New Thrombolytic Compound LT3001 on Acute Brain Tissue Damage After Focal Embolic Stroke in Rats

Article

作者: Zhou, Iris Yuwen ; Liu, Ning ; Dumont, Aaron S ; Wang, Xiaoying ; Ji, Yang ; Ning, Mingming ; Jiang, Yinghua ; Sun, Phillip Zhe

LT3001 is a novel synthetic small molecule with thrombolytic and free radical scavenging activities. In this study, we tested the effects of LT3001 as a potential alternative thrombolytic in focal embolic ischemic stroke rat model. Stroked rats received intravenous injection of 10 mg/kg LT3001 or tPA at 1.5, 3, or 4.5 h after stroke, respectively, and the outcomes were measured at different time points after stroke by performing multi-parametric MRI, 2,3,5-triphenyltetrazolium chloride (TTC) staining, and modified neurological severity score. Lastly, we assessed the effect of LT3001 on the tPA activity in vitro, the international normalized ratio (INR), and the serum levels of active tPA and plasminogen activator inhibitor-1 (PAI-1). LT3001 treated at 1.5 h after stroke is neuroprotective by reducing the CBF lesion size and lowering diffusion and T2 lesion size measured by MRI, which is consistent with the reduction in TTC-stained infarction. When treated at 3 h after stroke, LT3001 had significantly better therapeutic effects regarding reduction of infarct size, swelling rate, and hemorrhagic transformation compared to tPA. When treated at 4.5 h after stroke, tPA, but not LT3001, significantly increased brain swelling and intracerebral hemorrhagic transformation. Lastly, LT3001 did not interfere with tPA activity in vitro, or significantly alter the INR and serum levels of active tPA and PAI-1 in vivo. Our data suggests that LT3001 is neuroprotective in focal embolic stroke rat model. It might have thrombolytic property, not interfere with tPA/PAI-1 activity, and cause less risk of hemorrhagic transformation compared to the conventional tPA. Taken together, LT3001 might be developed as a novel therapy for treating thrombotic ischemic stroke.

2019-06-30·ACS Omega

Cardioprotection Effects of LPTC-5 Involve Mitochondrial Protection and Dynamics

作者: Hou, Shanshan ; Jockusch, Steffen ; Li, Pengfei ; Gibson, K. Michael ; Zhang, Yanrong ; Yan, Xin ; Bi, Yue ; Legalley, Thomas D. ; Bi, Wei ; Hensley, Connor ; Bi, Lanrong

We recently designed and synthesized a series of novel levodopa-peptide-TEMPO conjugates (LPTCs).Among these compounds, LPTC-5 possesses both free-radical scavenging potential and mitochondrial fusion-promoting activity.The free-radical scavenging capacity of LPTC-5 was confirmed using a PC12 cell survival assay.LPTC-5 could restore the mitochondrial tubular network following genetically induced fragmentation.The therapeutic efficacy of LPTC-5 was then examined employing in vitro and in vivo ischemia/reperfusion (I/R) models.LPTC-5 protected cells from mitochondrial reactive oxygen species overproduction and inhibited cytochrome c release in a simulated I/R cellular model.Addnl., LPTC-5 attenuated organ damage in a cardiac I/R animal model.The data suggest that LPTC-5 exerts cardioprotection via modulation of mitochondrial fission/fusion dynamics, ultimately improving mitochondrial function and cardiac function.

项与 Odatroltide 相关的新闻（医药）

2026-02-11

·医联生命服务

LT3001在致残性急性缺血性卒中患者中展现功能改善疗效

顺天医药今日公布其新型卒中药物LT3001（Odatroltide）两项独立的二期临床试验积极结果。LT3001是一种首创的双功能疗法，将安全再灌注与直接神经保护相结合，旨在解决当前急性缺血性卒中治疗的关键局限性。试验数据结果数据显示，LT3001为患有致残性急性缺血性卒中的患者带来具有临床意义的功能改善，为那些无法接受标准再灌注治疗的患者带来了新希望。该数据今日在新奥尔良举行的国际卒中会议上发布。这一突破性结果证明了LT3001有望为治疗选择有限的卒中患者改变治疗结局。这种新型治疗药物能增强内源性纤溶并清除有害自由基，在出现致残症状的中度卒中患者中显示出尤为显著的效果。在中国进行的LT3001-202试验中，与安慰剂相比，接受LT3001治疗的伴致残症状中度卒中患者，其改良Rankin量表评分达到0-1分和0-2分的比例分别提高了8%和13%。最值得注意的是，LT3001在大动脉粥样硬化型和影像错配阳性患者群体中均显示出功能结局的改善。在202研究中，LAA型患者（n=169）mRS评分0-2分的比例提高了11%，0-1分的比例提高了9%。205研究通过影像辅助选择验证了这些疗效信号，错配阳性患者的mRS 0-2分比例实现了10%的绝对改善。这些临床进展有望每年帮助数千名患者恢复独立生活能力。另一项在美国、欧盟和台湾进行的补充性LT3001-205试验采用了先进的影像辅助患者选择。尽管样本量较小，该试验进一步强化了LT3001的疗效信号：与安慰剂组（17%）相比，更多伴致残症状特征的患者在LT3001治疗下达到mRS 0-1分（27%）。 "在这两项二期试验中，LT3001展示了良好的安全性，尽管连续3天多次给药，但症状性颅内出血风险并未增加，" CHI Memorial神经科学研究所所长、莫尔豪斯医学院神经病学教授、LT3001-205研究主要研究者Thomas Devlin博士表示，"LT3001在传统溶栓时间窗外显示出潜在获益，支持其用于不符合静脉溶栓或血管内治疗条件的患者，这部分患者存在高度未满足的医疗需求。两项独立试验采用不同选择策略获得的一致性结果，增强了我们对LT3001广泛适用性的信心。" 应对关键的未满足需求 "尽管经过五十多年的研究和数千个潜在药物靶点的探索，针对卒中等的神经保护药物研发尚未在美国催生出任何FDA批准的药物，" 顺天医药总经理叶嘉文博士表示，"许多药物在临床前动物研究中经常成功，但在人体试验中却未能显示出安全性或有效性。我们在不同患者群体中获得的LT3001疗效数据令人振奋，并为我们的三期项目指明了方向。" 急性缺血性卒中全球影响数百万人，许多患者出现致残症状，严重影响其生活质量和独立性。当前的再灌注疗法虽然有效，但由于时间限制、禁忌症或解剖因素，并不适用于所有患者。LT3001独特的双重机制——增强人体天然溶栓过程同时保护脑组织免受氧化损伤——为这些未得到充分治疗的患者提供了新的治疗途径。试验评估了卒中发作24小时内的患者，重点关注定义为显著上肢或下肢运动障碍的致残症状患者。这部分患者占卒中病例的很大一部分，而当前的治疗方案仍不充足。两项二期试验均采用了严格的随机、安慰剂对照方法，其中LT3001-202研究入组了297名患者，LT3001-205研究入组了88名患者。积极信号在不同地理区域和患者选择标准中的一致性，凸显了这些研究结果的稳健性。关于LT3001 LT3001代表了一种治疗急性卒中的创新方法，同时针对卒中病理生理中的血栓形成和氧化应激成分。与仅关注清除血栓的传统方法不同，LT3001的双重机制针对卒中损伤的多个方面，有望延长治疗时间窗并扩大患者适用人群。公司正在通过全面的临床开发推进LT3001，计划开展三期试验，以在更大的患者群体中进一步验证这些前景广阔的结果。下一步及全球开发计划这些综合的二期结果为支持LT3001继续开发用于急性缺血性卒中提供了关键的临床证据。值得注意的是，顺天医药近期已收到美国食品药品监督管理局关于其LT3001三期开发计划的反馈。基于此反馈，顺天医药旨在加速LT3001的全球三期开发，为全球卒中患者提供创新有效的治疗选择。关于急性缺血性卒中根据世界卫生组织数据，卒中是60岁以上人群第二大死亡原因，全球每年约有600万人死亡。卒中可分为出血性（出血）或缺血性（脑部关键区域血流中断）。研究表明缺血性卒中最为常见，约占所有卒中病例的85%。卒中是一种全球医疗需求远未得到满足的重大疾病。全球每年有1500万人罹患卒中。由于目前仅有手术和有限的治疗方案可用，80%的卒中患者没有其他治疗选择或未能获得理想疗效。参考来源： https://www.prnewswire.com/ 免责声明：本公众号内容仅作交流参考，不作为诊断及医疗参考，专业医学问题请咨询专业人士或专业医疗机构。

2026-02-06

·PRNewswire

LT3001 DEMONSTRATES FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH DISABLING ACUTE ISCHEMIC STROKE

Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion Therapies Data Presented at International Stroke Conference Data Show That LT3001 Delivers Meaningful Functional Improvements in Patients Suffering from Disabling Acute Ischemic Stroke (AIS) TAIPEI, Feb. 6, 2026 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide). LT3001 is a first-in-class dual-functional therapy that combines safe reperfusion with direct neuroprotection, addressing key limitations of current acute ischemic stroke treatments. These data revealed that LT3001 delivers meaningful functional improvements in patients suffering from disabling acute ischemic stroke (AIS), offering new hope for those who cannot receive standard reperfusion treatments. These data were reported here today at the International Stroke Conference in New Orleans. The groundbreaking results demonstrate LT3001's potential to transform outcomes for stroke patients facing limited therapeutic options. The novel therapeutic agent, which enhances endogenous fibrinolysis and scavenges harmful free radicals, showed particularly impressive results in moderate stroke patients with disabling symptoms. In the LT3001-202 trial conducted in China, moderate stroke patients with disabling symptoms treated with LT3001 achieved 8% and 13% improvements in modified Rankin Scale (mRS) scores of 0-1 and 0-2 respectively, compared to placebo. Most remarkably, LT3001 showed improvement in functional outcomes in LAA and mismatch-positive populations. In Study 202, LAA patients (n=169) showed an 11% improvement in mRS 0–2 and a 9% gain in mRS 0–1. Study 205 validated these signals via imaging assisted selection, with mismatch-positive patients achieving a 10% absolute improvement in mRS 0–2. These clinical advances could restore independence to thousands of patients annually. The complementary LT3001-205 trial, spanning the US, EU, and Taiwan, utilized advanced imaging-assisted patient selection. Despite smaller sample sizes, the trial reinforced LT3001's efficacy signals, with patients showing disabling features achieving mRS 0-1 outcomes more often with LT3001 (27%) compared to placebo (17%). "Across the two Phase 2 trials, LT3001 demonstrated a favorable safety profile, with no increase in symptomatic intracranial hemorrhage (sICH) despite multi-dose administration over 3 days," said Thomas Devlin, MD, PhD, FSVIN, Director of the CHI Memorial Neuroscience Institute, Professor of Neurology Morehouse School of Medicine and principal investigator of the LT3001-205 study. "LT3001 showed potential benefit beyond the conventional thrombolytic time window, supporting its use in patients ineligible for IV thrombolysis or EVT, a population with high unmet need. The consistency of results across two independent trials, using different selection strategies, strengthens our confidence in LT3001's broad applicability." Addressing a Critical Unmet Need "Despite over five decades of research and thousands of potential drug targets, the development of neuroprotective drugs for conditions like stroke has not resulted in any FDA-approved drugs in the U.S.," said Sheng-Wen Yeh (Mimi) Ph.D., general manager, Lumosa. "While many drugs frequently succeed in preclinical, animal-based studies, they fail to show safety or efficacy in human trials. Our efficacy data with LT3001, spanning diverse patient populations, is exciting and provides direction for our Phase 3 programs." Acute ischemic stroke affects millions globally, with many patients experiencing disabling symptoms that severely impact their quality of life and independence. Current reperfusion therapies, while effective, are not suitable for all patients due to timing constraints, contraindications, or anatomical factors. LT3001's unique dual mechanism - enhancing the body's natural clot-dissolving processes while protecting brain tissue from oxidative damage - offers a new therapeutic pathway for these underserved patients. The trials evaluated patients within 24 hours of stroke onset, focusing on those with disabling symptoms defined as significant arm or leg motor impairment. This patient population represents a substantial portion of stroke cases where current treatment options remain inadequate. Both Phase 2 trials employed rigorous randomized, placebo-controlled methodologies, with LT3001-202 enrolling 297 patients and LT3001-205 including 88 patients. The consistency of positive signals across different geographic regions and patient selection criteria underscores the robustness of these findings. About LT3001 LT3001 (Odatroltide) represents an innovative approach to acute stroke treatment, targeting both the thrombotic and oxidative components of stroke pathophysiology. Unlike traditional approaches that focus solely on clot removal, LT3001's dual mechanism addresses multiple aspects of stroke injury, potentially extending the therapeutic window and broadening patient eligibility. The Company is advancing LT3001 through comprehensive clinical development, with plans for Phase 3 trials to further validate these promising results in larger patient populations. Next Steps and Global Development Plans These combined Phase 2 results provide critical clinical evidence supporting the continued development of LT3001 for acute ischemic stroke. Of note, Lumosa recently received feedback from the U.S. Food and Drug Administration regarding its Phase 3 development plans for LT3001. Based on this feedback, Lumosa aims to accelerate global Phase 3 development of LT3001 and deliver innovative and effective treatment options for stroke patients worldwide. About Acute Ischemic Stroke According to the World Health Organization (WHO), stroke is the second leading cause of death for people over the age of 60 with approximately 6 million deaths in the world per year. Stroke can be categorized as hemorrhagic (bleeding) or ischemic (lack of blood flow to critical areas of the brain). Studies show ischemic stroke is most common, occurring in about 85% of all stroke cases. Stroke is notably a disease with significant global unmet medical need. There are 15 million people worldwide who suffer a stroke each year. Because only surgery and limited therapeutic options are currently available, 80% of stroke patients are left with no other treatment options or without desired outcomes. About Lumosa Lumosa Therapeutics, Inc. () is a clinical-stage pharmaceutical company dedicated to the development of novel therapies and solutions for neurologic diseases with urgent unmet medical need. In addition to utilizing its own technology platform, the Company is also actively engaged in scientific licensing and co-development collaboration -- building a pipeline from early to late-stage assets consisting of first-in-class and best-in-class drugs. Lumosa's mission is to enrich patients' quality of life through pioneering medical science, diverse collaborations, and a commitment to remain genuine and ever-evolving. Central to this mission is the Company's objective to develop its novel small molecule, LT3001, for the treatment of acute ischemic stroke, a medical disease for which more effective therapies are greatly needed. SOURCE Lumosa Therapeutics Co., Ltd. 21% more press release views with Request a Demo

临床2期临床结果临床3期

2025-11-01

·药明康德

使超七成患者症状几乎完全清除的多肽疗法；潜在只需一年一次的长效siRNA减肥疗法…… | TIDES周报

近期，全球多肽和寡核苷酸（TIDES）领域迎来系列进展。强生（Johnson & Johnson）公布了其口服多肽疗法icotrokinra的两项临床试验结果，在斑块状银屑病和活动性溃疡性结肠炎患者中均取得了积极的疗效数据。Wave Life Sciences公司的长效siRNA减肥疗法WVE-007获积极临床数据，具备一年一次或一年两次给药的潜力。公布本文将节选其中部分重要进展做简单介绍，仅供读者参阅。 Icotrokinra：公布两项临床试验数据强生公布了其靶向口服多肽icotrokinra的两项临床试验的积极数据。Icotrokinra能够选择性阻断IL-23受体（IL-23R）。IL-23是银屑病和其他皮肤病、风湿病和IL-23介导肠胃病中炎症反应的基础。Icotrokinra能够以高亲和力与IL-23R结合，并对人类T细胞中的IL-23信号转导产生强效的选择性抑制作用。值得一提的是，icotrokinra曾在今年被知名产业媒体猎药人（Drug Hunter）评为2024年度十大明星分子之一。在针对成人和12岁及以上斑块状银屑病患者的3期临床试验ICONIC-TOTAL中，接受icotrokinra治疗的头皮银屑病和生殖器银屑病患者，在第52周时分别有72%和85%达到IGA 0/1分（皮损完全清除或几乎清除）；67%的患者在第24周时即达到IGA 0/1分，并持续维持至第52周。作为一种每日一次的口服药，icotrokinra持续展现出卓越的皮损清除效果和良好的安全性，具有显著的治疗潜力。在针对中度至重度活动性溃疡性结肠炎成人患者的2b期研究ANTHEM-UC中，icotrokinra在第28周持续展现出具有临床意义的疗效。结果显示，400 mg剂量组中，66.7%的中重度溃疡性结肠炎患者达到临床应答，31.7%达到临床缓解，38.1%实现内镜改善，疗效优于安慰剂。所有icotrokinra剂量组（100 mg、200 mg和400 mg）在临床缓解率、临床缓解、内镜改善及组织学-内镜黏膜改善（HEMI）等指标上均优于安慰剂组，且疗效自第12周起持续至第28周。这些结果进一步支持了icotrokinra在溃疡性结肠炎和克罗恩病中的3期临床开发。 ▲ANTHEM-UC研究的结果（图片来源：参考资料[3]） WVE-007：公布1期临床试验数据 Wave Life Sciences公司公布了其进行中INLIGHT临床试验的最新数据，该试验评估在研疗法WVE-007用于肥胖治疗的效果。WVE-007是一款长效GalNAc修饰siRNA，可靶向遗传学验证靶点INHBE的mRNA。WVE-007旨在通过抑制INHBE来降低脂肪累积，同时保留肌肉质量。本次公布的结果显示，在三个剂量梯度队列中，均观察到剂量依赖性且高度显著的Activin E水平下降（所有剂量组p<0.0001）。在单次给药后第29天，400 mg、240 mg和75 mg剂量组的Activin E平均降低幅度分别达到85%、75%和56%。其中，240 mg和400 mg剂量组的抑制水平已超过此前临床前研究中与脂肪减少相关的阈值。此外，在75 mg剂量组中，Activin E的下降趋势在长达6个月的随访中仍具持续性，显示WVE-007具备一年一次或一年两次给药的潜力。临床安全性方面，WVE-007目前耐受性良好，独立数据监测委员会已支持600 mg剂量队列扩展及更高剂量探索。玛仕度肽：公布3期临床试验数据信达生物宣布，其胰高血糖素（GCG）/胰高血糖素样肽-1（GLP-1）双受体激动剂玛仕度肽的第4项3期临床研究DREAMS-3达成主要终点。研究结果证明，在中国2型糖尿病合并肥胖受试者中，第32周时，玛仕度肽组糖化血红蛋白（HbA1c）＜7.0%且体重较基线下降≥10%的受试者比例为48.0%，优效于活性对照药组（21.0%，P值＜0.0001）。此外，第32周时，玛仕度肽组和活性对照药组HbA1c较基线变化均值分别为−2.03%和−1.84%，体重较基线平均百分比降幅分别为10.29%和6.00%（P值均＜0.05）。研究期间玛仕度肽整体安全性特征与既往临床研究一致，未发现新增安全性信号。胃肠道不良反应是最常见的不良事件，多为轻度或中度。玛仕度肽是信达生物与礼来（Eli Lilly and Company）共同推进的一款GCG/GLP-1双受体激动减重药物，其具有独特的双激动作用机制，在激动GLP-1受体抑制食欲的基础上，同时激活GCG受体，促进脂肪燃烧，降低内脏脂肪含量，进一步增强玛仕度肽减重效果。玛仕度肽已在多项临床研究中展现出优秀的减重和降糖疗效，以及降低腰围、血脂、血压、血尿酸、肝酶及肝脏脂肪含量，并改善胰岛素敏感性，带来多重代谢获益。该疗法已在中国获批两项适应症，包括肥胖或超重并伴有至少一种体重相关的合并症的成人患者的长期体重控制，以及成人2型糖尿病患者的血糖控制。 120亿美元！诺华收购Avidity Biosciences 诺华（Novartis）日前宣布达成协议，将以约120亿美元收购Avidity Biosciences，此交易将在Avidity分拆其早期精准心脏病学项目后完成。Avidity致力于开发抗体寡核苷酸偶联物（AOC）类的新型RNA疗法，用于治疗严重的遗传性神经肌肉疾病。此次收购将使诺华获得Avidity的后期神经科学项目，并引入一个差异化的RNA靶向递送平台，进一步丰富其神经科学研发布局。该收购预计将推动诺华的神经科学战略发展，并补充其管线中针对肌肉损伤疾病遗传驱动因素的潜在“first-in-class”疗法。本次收购将为诺华带来三项处于后期阶段、针对遗传性神经肌肉疾病的项目，包括：目前无有效疾病修饰疗法的罕见进行性疾病I型肌强直性营养不良（DM1）、导致持续性肌肉功能丧失的罕见遗传病面肩肱型肌营养不良（FSHD）、以及严重早发、以进行性肌肉损伤和寿命缩短为特征的杜氏肌营养不良症（DMD）。参考资料： [1] 降糖减重双优效，玛仕度肽头对头司美格鲁肽. Retrieved October 31, 2025, from https://www.prnasia.com/story/508685-1.shtml [2] Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis. Retrieved October 31, 2025, from https://www.prnewswire.com/news-releases/icotrokinra-long-term-results-affirm-promise-of-targeted-oral-peptide-with-high-rates-of-durable-skin-clearance-and-favorable-safety-profile-in-difficult-to-treat-scalp-and-genital-psoriasis-302593288.html [3] Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis. Retrieved October 31, 2025, from https://www.prnewswire.com/news-releases/icotrokinra-maintains-standout-combination-of-therapeutic-benefit-and-a-favorable-safety-profile-in-once-daily-pill-through-28-weeks-in-ulcerative-colitis-302594371.html [4] LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE. Retrieved October 31, 2025, from https://www.prnewswire.com/news-releases/lumosa-therapeutics-announces-positive-results-from-lt3001intravenous-odatroltide-phase-2b-clinical-trial-in-acute-ischemic-stroke-302596427.html [5] Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women. Retrieved October 31, 2025, from https://www.globenewswire.com/news-release/2025/10/23/3172057/0/en/Entera-Bio-Presents-Positive-New-Clinical-Data-from-EB613-Phase-2-Trial-Demonstrating-Significant-Bone-Density-Improvements-in-Early-Postmenopausal-Women.html [6] Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day. Retrieved October 31, 2025, from https://www.globenewswire.com/news-release/2025/10/29/3176880/0/en/Wave-Life-Sciences-Announced-Positive-Target-Engagement-Data-from-INLIGHT-Clinical-Trial-of-WVE-007-for-Obesity-During-Annual-Research-Day.html [7] CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment. Retrieved October 31, 2025, from https://www.prnewswire.com/news-releases/cage-bio-announces-start-of-phase-2-clinical-trial-of-novel-topical-dna-aptamer-therapy-cgb-600-for-vitiligo-treatment-302592881.html [8] Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity. Retrieved October 31, 2025, from https://www.prnewswire.com/news-releases/vial-initiates-phase-1-trial-of-vial-inhbe-an-inhbe-activin-e-sirna-for-the-treatment-of-obesity-302592339.html [9] 中国国家药监局药品审评中心（CDE）官网. Retrieved October 31, 2025, from https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c [10] Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline. Retrieved October 27, 2025 from https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline [11] GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases. Retrieved October 28, 2025 from https://www.empiri.co/press-releases/gsk-and-empirico-enter-license-agreement-for-clinical-stage-first-in-class-oligonucleotide-candidate-to-treat-respiratory-diseases/ 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

siRNA临床3期临床结果临床2期寡核苷酸

100 项与 Odatroltide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑卒中	临床2期	美国	上海医药集团股份有限公司	2022-07-21
急性缺血性卒中	临床2期	美国	顺天医药生技股份有限公司	2020-01-27
急性缺血性卒中	临床2期	中国台湾	顺天医药生技股份有限公司	2020-01-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04809818 (CTgov)	临床1期	急性缺血性卒中	65	LT3001 drug product (Part A - LT3001 Drug Product)	壓憲範窪觸齋構顧蓋鹹 = 鏇簾積壓願鏇積醖窪衊蓋繭鏇鑰夢觸憲顧夢鹹 (鑰鹹築壓願餘憲衊餘選, 壓鏇築壓獵遞廠構顧膚 ~ 選鹽淵鏇願襯觸窪構製) 更多	-	2026-02-06
				Placebo (Part A - Placebo)	壓憲範窪觸齋構顧蓋鹹 = 繭鬱觸窪餘簾襯衊繭範蓋繭鏇鑰夢觸憲顧夢鹹 (鑰鹹築壓願餘憲衊餘選, 鹽壓顧蓋顧窪壓淵衊糧 ~ 鹹鬱齋膚築積夢獵製簾) 更多
NCT04091945 (LT3001, CTgov)	临床2期	急性缺血性卒中	24	LT3001 Drug Product (LT3001 Drug Product)	鹹積艱製廠觸鹹壓襯餘 = 鏇餘選繭積餘鬱網選壓憲醖網遞鹽廠襯鬱獵壓 (觸窪鹽鬱窪獵窪獵簾觸, 壓築齋構觸鑰壓獵膚齋 ~ 齋構積齋鑰鑰遞衊餘簾) 更多	-	2025-12-30
				Placebo (Placebo)	鹹積艱製廠觸鹹壓襯餘 = 窪鏇蓋糧願築顧選齋遞憲醖網遞鹽廠襯鬱獵壓 (觸窪鹽鬱窪獵窪獵簾觸, 餘範淵範淵艱膚艱醖獵 ~ 構襯醖繭襯鹹獵齋醖餘) 更多
NCT05403866 (LT3001-205 \| BRIGHT, CTgov)	临床2期	急性缺血性卒中	89	LT3001 Drug Product (LT3001 Drug Product)	淵夢衊壓範餘選積夢獵 = 廠築製製鏇觸遞範遞齋淵觸繭願繭簾窪範選齋 (構膚繭餘襯選鹽繭顧選, 遞願鏇網膚壓艱鏇夢鏇 ~ 積艱壓襯範艱醖鹹淵製) 更多	-	2025-12-26
				Placebo (Placebo)	淵夢衊壓範餘選積夢獵 = 構製鹽襯鑰網獵鑰網獵淵觸繭願繭簾窪範選齋 (構膚繭餘襯選鹽繭顧選, 壓構築製網齋遞醖襯餘 ~ 簾蓋廠築顧鹹網獵願構) 更多
LT3001-202 (PRNewswire) 人工标引	临床2期	急性缺血性卒中	-	LT3001	願餘簾糧憲簾遞衊願糧(壓艱襯糧鹽襯簾壓鹽廠) = The China Phase 2b study met its primary endpoint of safety. No treatment-related symptomatic intracranial hemorrhage (sICH) was observed. Across all treatment groups, LT3001 demonstrated a consistent trend of functional improvement compared with placebo 夢鑰壓襯範淵蓋淵齋鹹 (憲構積簾廠鬱憲獵觸範 ) 达到	积极	2025-10-28
				LT3001 (Moderate strokes)
NCT05403866 (LT3001-205, PRNewswire) 人工标引	临床2期	急性缺血性卒中	88	LT3001	顧艱憲壓願壓觸鹹廠範(製糧廠顧網壓壓遞醖艱) = met its primary safety endpoint. No treatment-related sICH was observed. 壓繭齋膚壓願網艱夢廠 (餘獵製襯鹽構壓襯獵齋 ) 达到	积极	2025-10-28
				LT3001 (Disabling strokes with arm motor drift)
NCT05403866 (NEWS) 人工标引	临床2期	急性缺血性卒中	-	LT3001	鹹餘鏇遞網製顧鬱衊廠(範鹽壓夢鑰憲艱壓願遞) = LT3001 注射液总体安全耐受性良好。憲顧鬱鏇顧醖廠鹽繭鏇 (襯餘繭壓製顧鏇鏇鑰構 )	积极	2024-11-30
NCT04091945 (LT3001, Pubmed \| Drug Des Devel Ther)	临床2期	急性缺血性卒中	24	Odatroltide (LT3001) 0.025 mg/kg	獵鬱淵淵糧憲簾艱憲簾(網淵築鏇蓋網醖蓋鏇遞) = 鬱顧艱願壓簾鏇網簾衊齋鹹齋鬱遞製構艱壓鹹 (顧糧築餘觸夢願獵餘築 ) 更多	积极	2024-01-01
				Placebo	獵鬱淵淵糧憲簾艱憲簾(網淵築鏇蓋網醖蓋鏇遞) = 糧鬱醖糧憲淵壓鬱積製齋鹹齋鬱遞製構艱壓鹹 (顧糧築餘觸夢願獵餘築 ) 更多
NCT04091945 (Corporate Publications) 人工标引	临床2期	急性缺血性卒中	24	LT3001	簾鏇餘簾製觸膚憲鑰選(獵鹽範積製齋襯糧範醖) = no evidence of increased risk 觸鑰艱襯糧鹹網醖醖築 (糧願網鏇製製糧餘鹹範 )	积极	2021-08-03
				Placebo